Biomedicines (Jan 2021)

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer

  • Patricia Mondelo-Macía,
  • Jorge García-González,
  • Luis León-Mateos,
  • Adrián Castillo-García,
  • Rafael López-López,
  • Laura Muinelo-Romay,
  • Roberto Díaz-Peña

DOI
https://doi.org/10.3390/biomedicines9010048
Journal volume & issue
Vol. 9, no. 1
p. 48

Abstract

Read online

Approximately 19% of all cancer-related deaths are due to lung cancer, which is the leading cause of mortality worldwide. Small cell lung cancer (SCLC) affects approximately 15% of patients diagnosed with lung cancer. SCLC is characterized by aggressiveness; the majority of SCLC patients present with metastatic disease, and less than 5% of patients are alive at 5 years. The gold standard of SCLC treatment is platinum and etoposide-based chemotherapy; however, its effects are short. In recent years, treatment for SCLC has changed; new drugs have been approved, and new biomarkers are needed for treatment selection. Liquid biopsy is a non-invasive, rapid, repeated and alternative tool to the traditional tumor biopsy that could allow the most personalized medicine into the management of SCLC patients. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) are the most commonly used liquid biopsy biomarkers. Some studies have reported the prognostic factors of CTCs and cfDNA in SCLC patients, independent of the stage. In this review, we summarize the recent SCLC studies of CTCs, cfDNA and other liquid biopsy biomarkers, and we discuss the future utility of liquid biopsy in the clinical management of SCLC.

Keywords